Blog
RSS FeedPosted by Michael Wonder on 16 Jan 2024
Ono Pharm’s Braftovi for BRAF V600E mutated colorectal cancer gets reimbursement
11 January 2024 - Ono Pharmaceutical Korea said Thursday that Braftovi (encorafenib), a targeted therapy for BRAF V600E mutated metastatic ...
Posted by Michael Wonder on 08 Jan 2024
'GSK's immunotherapy Jemperli paves way for second-line endometrial cancer treatment'
7 December 2023 - GSK's immunotherapy Jemperli (dostarlimab) is set to play a key role in the second-line treatment of ...
Posted by Michael Wonder on 29 Nov 2023
Patients on edge as drug price bargaining for Braftovi prolongs
28 November 2023 - Health insurance coverage for the colon cancer drug Braftovi (encorafenib) is unlikely to be available this ...
Posted by Michael Wonder on 26 Nov 2023
Xtandi to get expanded coverage for metastatic hormone sensitive prostate cancer next month
31 October 2023 - Prostate cancer drug Xtandi (enzalutamide), in combination with androgen deprivation therapy to treat patients with metastatic ...
Posted by Michael Wonder on 26 Nov 2023
‘Verzenio, a ray of hope for breast cancer patients, should get insurance benefits’
24 November 2023 - A petition has been posted to call for providing insurance benefits for Lilly's CDK 4/6 inhibitor ...
Posted by Michael Wonder on 24 Nov 2023
Atopic dermatitis drug Adtralza passes insurance panel at ultrafast speed
10 November 2023 - LEO Pharma's Adtralza (tralokinumab), the second biologic approved to treat atopic dermatitis, and GSK's Trelegy 200 ...
Posted by Michael Wonder on 24 Nov 2023
Handok's Vyxeos, Gilead's Trodelvy pass cancer drug review for insurance coverage
23 November 2023 - Handok’s Vyxeos liposomal Injection, a combination of cytarabine and daunorubicin for therapy-related acute myeloid leukaemia and ...
Posted by Michael Wonder on 08 Nov 2023
Gilead Sciences Korea seeks reimbursement for Trodelvy
8 November 2023 - Gilead Sciences Korea is seeking insurance coverage of its new drug Trodelvy (sacituzumab govitecan) for the ...
Posted by Michael Wonder on 07 Nov 2023
Patients upset over repeated failures to reimburse blood cancer drugs
6 November 2023 - As drugs demonstrating superior efficacy over existing standard treatments for blood cancers repeatedly failed to get ...
Posted by Michael Wonder on 06 Nov 2023
Expanded reimbursement for Spinraza improves patient access
2 November 2023 - Biogen Korea is strengthening its position in the local spinal muscular atrophy market with expanded reimbursement ...
Posted by Michael Wonder on 04 Nov 2023
Handok paves the way for a smooth introduction of its new cancer drug
2 November 2023 - The first was Vyxeo, approved by the Ministry of Food and Drug Safety in November last ...
Posted by Michael Wonder on 06 Sep 2023
'Joint reimbursement of Opdivo, CDx platform marks milestone in gastric cancer but challenges remain'
6 September 2023 - Oncology experts celebrated the joint reimbursement of Opdivo together with its PD-L1 IHC 28-8 PharmDx companion ...
Posted by Michael Wonder on 21 Aug 2023
Patients get antsy amid protracted price bargaining for Spinraza, Evrysdi
21 August 2023 - Drug price negotiations for two spinal muscular atrophy drugs --Spinraza (nusinersen sodium) and Evrysdi (risdiplam) – ...
Posted by Michael Wonder on 31 Jul 2023
Bavencio gets coverage as first-line maintenance therapy for urothelial cancer
25 July 2023 - Merck’s anti-PD-L1 immuno-oncology drug Bavencio (avelumab) will get insurance coverage starting next month as first-line maintenance ...
Posted by Michael Wonder on 19 Jul 2023
Severe asthma treatment Cinqair passes drug review 6 years after approval
7 July 2023 - Teva Handok's severe asthma treatment Cinqair (reslizumab) crossed the threshold of the Drug Benefit Evaluation Committee ...